drugset / Trial / NCT04894123
Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
Phase 2
Terminated
1 enrolled
GERCOR - Multidisciplinary Oncology Cooperative Group
Servier · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related thoracic pain due to fluoropyrimidines in the adjuvant or metastatic setting .
Timeline
- Start
- 2022-02-07
- Primary completion
- 2023-02-13
- Completion
- 2023-02-13
Outcome
Outcome not reported
Stopped (Enrollment): “Recruitment failure”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Trifluridine/Tipiracil | Unknown | 35 mg/m2 | Oral |